Percent True Calcium Absorption, Mineral Metabolism, and Bone Mineralization in Children with Cystic Fibrosis: Effect of Supplementation with Vitamin D and Calcium
Overview
Pulmonary Medicine
Authors
Affiliations
Objective: To assess whether percent true calcium absorption (alpha) is normal in children with cystic fibrosis (CF) and to assess whether supplementation with 2,000 IU vitamin D(3), 1 g calcium, or both will alter alpha, mineral metabolism, and/or bone mass in children with CF.
Study Design: Fifteen children ages 7-13 were randomly assigned to one of four different orders to receive all four 6-month treatments including placebos. Change in 25-hydroxyvitamin D (25-OHD), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), PTH, bone turnover markers, and minerals after 6 months, and bone mineral content (Hologic 1000W) after 9 months was measured. alpha was measured by a dual stable isotope method using (48)Ca intravenously and (46)Ca orally and measuring (48)Ca, (46)Ca, and (42)Ca in a 24-hr urine using High Resolution Inductively Coupled Mass Spectroscopy (HR-ICP-MS). Analysis used Wilcoxon Sign Ranks.
Results: alpha was in the normal range and did not differ by treatment (P 35 +/- 10%, Ca 38 +/- 23%, D 36 +/- 11%, D + Ca 46 +/- 21%). One gram calcium did not increase serum or urine calcium. Two thousand IU D(3) did not increase 25-OHD or change 1,25(OH)(2)D. Serum and urine minerals, markers of bone turnover and bone mineral gains did not differ by treatment.
Conclusions: alpha is normal in children with CF. One gram calcium and/or 2,000 IU D(3) does not change alpha or increase 25-OHD, serum calcium, or mineralization. Longer trials of a significantly higher dose of vitamin D(3) shown to increase serum 25-OHD are needed to assess effects on mineral metabolism and bone mass accrual. However, study of therapeutic options other than calcium and vitamin D should be encouraged.
Endocrine Disorders in Cystic Fibrosis.
Blackman S, Tangpricha V Pediatr Clin North Am. 2016; 63(4):699-708.
PMID: 27469183 PMC: 5354098. DOI: 10.1016/j.pcl.2016.04.009.
Vitamin D supplementation for cystic fibrosis.
Ferguson J, Chang A Cochrane Database Syst Rev. 2014; (5):CD007298.
PMID: 24823922 PMC: 11254375. DOI: 10.1002/14651858.CD007298.pub4.
Vitamin d deficiency in cystic fibrosis.
Hall W, Sparks A, Aris R Int J Endocrinol. 2010; 2010:218691.
PMID: 20148079 PMC: 2817861. DOI: 10.1155/2010/218691.
Benefit-risk assessment of vitamin D supplementation.
Bischoff-Ferrari H, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett W Osteoporos Int. 2009; 21(7):1121-32.
PMID: 19957164 PMC: 3062161. DOI: 10.1007/s00198-009-1119-3.
Khazai N, Judd S, Jeng L, Wolfenden L, Stecenko A, Ziegler T J Clin Endocrinol Metab. 2009; 94(6):2037-43.
PMID: 19336509 PMC: 2690417. DOI: 10.1210/jc.2008-2012.